Given that CLEC2D induction requires robust and sustained immune activation [48], it would be interesting to investigate the potential of CD4+LLT1+ T cells as peripheral blood predictive biomarkers for immunotherapy responses and cancer remission. This evidence concerns the gene CLEC2D and cancer.